2025.08.01本文字数:510,阅读时长大约1.3分钟导读:默沙东上半年营收313亿美元微降2%,中国业务跳水七成拖累整体;HPV疫苗腰斩、K药放缓,公司急推30亿美元瘦身计划押注新药。昨日,默沙东发布2025年上半年财报:营收313.35亿美元,同比下滑2%。中国业务成为最大短板,本土制药收入跳水七成至10.75亿美元,全球占比从4.9%跌至3.9%。明星产品Gardasil/...
Source Link2025.08.01本文字数:510,阅读时长大约1.3分钟导读:默沙东上半年营收313亿美元微降2%,中国业务跳水七成拖累整体;HPV疫苗腰斩、K药放缓,公司急推30亿美元瘦身计划押注新药。昨日,默沙东发布2025年上半年财报:营收313.35亿美元,同比下滑2%。中国业务成为最大短板,本土制药收入跳水七成至10.75亿美元,全球占比从4.9%跌至3.9%。明星产品Gardasil/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.